Package Leaflet: Information for the User
Tractocile 6.75 mg/0.9 ml Solution for Injection
atosiban
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Contents of the Package Leaflet
Tractocile contains atosiban. Tractocile may be used to delay premature birth of your baby. Tractocile is used in pregnant women from the 24th week up to the 33rd week of pregnancy.
Tractocile works by making the contractions of your uterus (womb) less strong. It also makes the contractions happen less often. This happens because it stops the natural hormone called "oxytocin", which makes the uterus contract, from working.
Do not use Tractocile
Do not use Tractocile if you are affected by any of these conditions. If you are not sure, tell your doctor, midwife or pharmacist before you are given Tractocile.
Warnings and precautions
Talk to your doctor, midwife or pharmacist before you are given Tractocile:
If you have any of these conditions (or are not sure), tell your doctor, midwife or pharmacist before you are given Tractocile.
Children and adolescents
Tractocile has not been studied in pregnant women under 18 years of age.
Using Tractocile with other medicines
Tell your doctor, midwife or pharmacist if you are taking, have recently taken or might take any other medicines.
Pregnancy and breast-feeding
If you are pregnant and breast-feeding, you should stop breast-feeding during treatment with Tractocile.
Tractocile will be given to you in a hospital by a doctor, nurse or midwife. They will decide how much you need. They will also check that the solution is clear and free of particles.
Tractocile will be given into a vein (intravenously) in three stages:
The total duration of treatment should not be more than 48 hours. You can have more treatments with Tractocile if you have contractions again. Treatment with Tractocile should not be repeated more than three times during a pregnancy.
During treatment with Tractocile, your contractions and your baby's heart rate can be monitored.
It is recommended not to repeat treatment more than three times during a pregnancy.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The side effects seen in mothers were generally mild. There are no known side effects on the fetus or newborn.
The following side effects may occur with this medicine:
Very common(affect more than 1 in 10 people)
Common(affect less than 1 in 10 people)
Uncommon(affect less than 1 in 100 people)
Rare(affect less than 1 in 1,000 people)
You may experience difficulty breathing or fluid in the lungs (pulmonary oedema), particularly if you are pregnant with more than one baby and/or are taking other medicines that may delay the birth of your baby, such as medicines used for high blood pressure.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of the month stated.
Store in a refrigerator (2°C - 8°C).
Store in the original package to protect from light.
Once the vial is opened, the product should be used immediately.
Do not use this medicine if you notice particles or discolouration of the contents before administration.
Composition of Tractocile
Appearance of Tractocile and contents of the pack
Tractocile 6.75 mg/0.9 ml solution for injection is a clear, colourless solution without particles. One pack contains one vial containing 0.9 ml of solution.
Marketing authorisation holder and manufacturer
Marketing authorisation holder:
Ferring Pharmaceuticals A/S
Amager Strandvej 40, 2770 Kastrup, Denmark
Tel: +45 88 33 88 34
Manufacturer:
Ferring GmbH
Wittland 11, D-24109 Kiel, Germany
You can get more information about this medicine by contacting the local representative of the marketing authorisation holder.
Belgium Ferring N.V. Tel: +32 53 72 92 00 ferringnvsa@ferring.be | Lithuania CentralPharma Communication UAB Tel: +370 5 243 0444 centralpharma@centralpharma.lt |
Bulgaria Farmont Ltd. Tel: +359 2 807 5022 farmont@farmont.bg | Luxembourg Ferring N.V. Belgium Tel: +32 53 72 92 00 ferringnvsa@ferring.be |
Czech Republic Ferring Pharmaceuticals CZ s.r.o. Tel: +420 234 701 333 cz1-info@ferring.com | Hungary Ferring Magyarország Gyógyszerkereskedelmi Kft. Tel: +36 1 236 3800 ferring@ferring.hu |
Denmark Ferring Lægemidler A/S Tel: +45 88 16 88 17 | Malta E.J. Busuttil Ltd. Tel: +356 21447184 info@ejbusuttil.com |
Germany Ferring Arzneimittel GmbH Tel: +49 431 5852 0 info-service@ferring.de | Netherlands Ferring B.V. Tel: +31 235680300 infoNL@ferring.com |
Estonia CentralPharma Communication OÜ Tel: +372 601 5540 centralpharma@centralpharma.ee | Norway Ferring Legemidler AS Tel: +47 22 02 08 80 mail@oslo.ferring.com |
Greece Ferring Ελλάς ΜΕΠΕ Tel: +30 210 68 43 449 | Austria Ferring Arzneimittel Ges.m.b.H Tel: +43 1 60 808 0 office@ferring.at |
Spain Ferring S.A.U. Tel: +34 91 387 70 00 registros@ferring.com | Poland Ferring Pharmaceuticals Poland Sp. z o.o. Tel: +48 22 246 06 80 PL0-Recepcja@ferring.com |
France Ferring S.A.S. Tel: +33 1 49 08 91 23 information.medicale@ferring.com | Portugal Ferring Portuguesa – Produtos Farmacêuticos, Sociedade Unipessoal, Lda. Tel: +351 21 940 51 90 |
Croatia Clinres farmacija d.o.o. Tel: +385 1 2396 900 | Romania Ferring Pharmaceuticals Romania SRL Tel: +40 356 113 270 |
Ireland Ferring Ireland Ltd. Tel: +353 1 4637355 EnquiriesIrelandMailbox@ferring.com | Slovenia SALUS, Veletrgovina, d.o.o. Tel: +386 1 5899 179 regulatory@salus.si |
Iceland Vistor hf. Tel: +354 535 70 00 | Slovakia Ferring Slovakia s.r.o. Tel: +421 2 54 416 010 SK0-Recepcia@ferring.com |
Italy Ferring S.p.A. Tel: +39 02 640 00 11 | Finland Ferring Lääkkeet Oy Tel: +358 207 401 440 info@ferring.fi |
Cyprus
Tel: +357 22583333 a.potamitismedicare@cytanet.com.cy | Sweden Ferring Läkemedel AB Tel: +46 40 691 69 00 info@ferring.se |
Latvia CentralPharma Communication SIA Tel: +371 674 50497 centralpharma@centralpharma.lv | United Kingdom (Northern Ireland) Ferring Ireland Ltd. Tel: +353 1 4637355 EnquiriesIrelandMailbox@ferring.com |
Date of last revision of this leaflet
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
---------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
(See also section 3).
Instructions for use:
Before using Tractocile, the solution should be examined to ensure it is clear and free of particles.
Tractocile is administered intravenously in three successive stages:
The total duration of treatment should not be more than 48 hours. New cycles of treatment with Tractocile may be given if contractions occur again. It is recommended not to repeat treatment more than three times during a pregnancy.